What actually happens to a founder's shares at listing?
Almost nothing, for the better part of a year. The company sells newly issued stock, a negotiated slice of existing holders may sell alongside it, and the founder is typically locked. The listing creates a public price for the shares. It does not create the ability to sell them.
The current market has the clearest published illustration of this in years. The largest US listing of 2026 carried a 180-day cohort released in stages, with 20% released after the first quarterly earnings report, a further 7% on each of five dates from 20 August to 24 October 2026, another 28% after the following quarter, and the balance free on 8 December 2026. Founder shares carried a 366-day lock running to 12 June 2027 with no early release provision at all, and shares under the extended lockup plus founder shares came to roughly 7.8 billion shares, more than 63% of the shares outstanding immediately before the offering (SpaceX Form 424B4 prospectus, filed 12 June 2026).
Read that structure back to front and the point is obvious. Two-thirds of the equity was contractually unable to move for between six months and a year, and the person who built the business was in the group that could not move at all. Whatever a listing is, for that holder it was not an exit.
The distinction matters because owners routinely price the decision as though it were one. A sale converts equity into cash on a known date at a known price. A listing converts equity into a marked position that you may be able to sell later, at a price nobody controls, in tranches somebody else scheduled.
Why are lockups now tied to share price performance?
Because underwriters learned that a calendar release into a falling market is bad for everybody, so release is increasingly conditioned on the stock doing well. The effect for a founder is that underperformance has a mechanical consequence: the shares stay locked.
The same 2026 prospectus is the worked example. An additional 10% would have released early only if the stock closed at or above $175.50, which is 30% above the $135 offer price, on at least five of the ten trading days ending on the first earnings date. Over that window the stock traded between $108.27 and $125.33, so the count was zero of ten and the tranche did not release (lockup condition from the Form 424B4 filed 12 June 2026; the price window is derived from the daily series, as of 5 August 2026).
That is worth restating plainly because the detail is easy to get wrong. The stock did trade well above the threshold shortly after listing, reaching $211.39 on 16 June, four days after pricing at $135. The condition was not about the high. It was about a specific ten-day window months later, by which time the stock had fallen below its offer price. A holder who assumed the early release had been earned would have been wrong.
The general instruction for anyone negotiating a 2027 listing is to read the release mechanics as carefully as the price talk, and to model the case where none of the contingent tranches vest. A lockup schedule is the only part of the transaction that determines when you are actually paid.
“An owner asks what the company is worth on listing day, and the honest answer is that the number on the screen is not the number they will receive. They will sell in tranches, over a year or more, into whatever market exists then, under a schedule negotiated by people whose interests are close to theirs but not identical. That is a very different instrument from a cheque at closing.”
What does the aftermarket record say about the eventual price?
That the offer price is a poor forecast of the exit price, and that the direction has more often been down than up. Measured today, the 2024 class of US operating-company listings shows a median return against offer of minus 43.2%, with 62% below offer, and the 2025 class shows minus 23.4%, also with 62% below offer. The 2026 class currently sits at plus 2.3% (derived from the Stock Analysis 2024, 2025 and 2026 US IPO tables, as of 6 August 2026).
The first-day premium has also halved. The Americas class of the first half of 2026 traded up 14% at one day after offer and 11% at thirty days, against 33% and 20% for the class of 2025 (EY Global IPO Trends Q2 2026, published 7 July 2026). For an issuer that is arguably better pricing; for a holder waiting to sell into the aftermarket it is a thinner cushion.
Sponsor-backed listings have had the flattest ride of all. The two sponsor-backed consumer deals that priced at the end of July 2026 returned 0.6% and 7.5%, against biotech listings in the same month returning between roughly 29% and 66% (derived from the Stock Analysis 2026 US IPO table, as of 5 August 2026). A sponsor exit through a listing in this market should be underwritten to no pop at all.
None of this argues that listing is a mistake. It argues that the listing price is the beginning of a distribution of outcomes rather than a realized value, and that the owner who compares an offer price to a private sale price is comparing a forecast to a cheque.
How does the job change once the company is listed?
It becomes a reporting job with an operating component, rather than an operating job with a reporting component. The management calendar reorganizes around quarterly results, guidance, investor meetings and the disclosure obligations that sit around all three, and the cost of being wrong in public is immediate and visible.
The listing venue itself is now a more active counterparty than it used to be. Nasdaq may deny an initial listing even where an applicant meets every stated requirement, citing manipulation risk in recently listed securities (SEC Release 34-104464, SR-NASDAQ-2025-104, filed 12 December 2025 and immediately effective). Meeting the published standards is no longer sufficient to guarantee admission, and the continued-listing standards are being tightened separately.
Some of that tightening is settled and some is not. The minimum market value of unrestricted publicly held shares rose to $15 million on both the Nasdaq Capital Market and the Nasdaq Global Market, operative from around 17 January 2026 (SEC Release 34-104450, SR-NASDAQ-2025-068). A separate proposal to impose a $5 million continued-listing market value requirement with no cure period was approved on 22 July 2026 and then stayed on 29 July 2026 pending Commission review, and it remained stayed as of 5 August 2026 (SEC Release 34-105971 and the Deputy Secretary's letter of 29 July 2026). Anyone told that the $5 million rule is in force today has been told something incorrect.
The practical consequence for a smaller issuer is that the obligations of being listed are rising while the benefits of being listed are concentrating at the top of the market. That is a governance question as much as a valuation one, and it is the reason the decision deserves to be taken on the post-listing job rather than on the listing-day headline.
So how should an owner compare a listing to a sale?
On four axes, none of which is the headline valuation: when you are paid, how certain the amount is, what you still have to do afterwards, and what the alternatives are if the market moves against you.
On timing, a sale pays at closing subject to escrow and any contingent consideration, while a listing pays in scheduled tranches over six to eighteen months. On certainty, a sale price is negotiated and fixed while a listing price is discovered daily; the 2024 and 2025 aftermarket figures above are the honest distribution around it. On the job, a sale usually ends or transforms the owner's role within a defined transition, while a listing extends it under new obligations.
On alternatives, the private route has broadened considerably. Continuation vehicles, secondaries and structured minority sales all now produce partial liquidity without a listing, and a large tracked universe of private companies carries public-style marks without public reporting: 325 private companies were tracked at an aggregate valuation of $5.3 trillion as of early August 2026 (Stock Analysis, private company valuations, as of 5 to 6 August 2026). Owners can obtain a mark and partial cash without accepting the disclosure regime.
The conclusion is not that listings are bad. It is that a listing answers a capital question, and most owners asking about an IPO are asking a liquidity question. Those two questions have different right answers, and confusing them costs a year and a lockup schedule to discover.
| Question | Private sale | Listing |
|---|---|---|
| When are you paid? | At closing, subject to escrow, any holdback and any contingent consideration | In scheduled tranches after the lockup, typically six to eighteen months, with founder shares often on the longest schedule |
| How certain is the amount? | Negotiated and fixed at signing, then adjusted by defined mechanisms | Discovered daily; the 2024 class of US operating-company listings sits at a median minus 43.2% against offer and the 2025 class at minus 23.4%, measured today |
| What happens to the job? | Ends or transforms within a defined transition period | Continues under quarterly reporting, guidance and disclosure obligations, with the venue able to refuse or remove a listing on its own judgment |
| What if the market turns? | The process can be paused, restructured or abandoned before signing | The lockup schedule keeps running, and performance-contingent tranches simply fail to release |
As of August 2026
Sources: SpaceX Form 424B4 prospectus, filed 12 June 2026, for the staged 180-day lockup schedule, the 366-day founder lock running to 12 June 2027 with no early release, the roughly 7.8 billion shares under extended lock and founder lock representing more than 63% of shares outstanding immediately before the offering, and the terms of the conditional early-release tranche requiring a close at or above $175.50 on at least five of the ten trading days ending on the first earnings date; daily price series for the same issuer, as of 5 August 2026, for the $135 offer on 12 June 2026, the $211.39 high on 16 June, the $108.27 to $125.33 range across the qualifying window that produced zero of ten qualifying days, and the close of $108.27 at minus 19.8% against offer; Stock Analysis 2024, 2025 and 2026 US IPO tables, as of 5 to 6 August 2026, for operating-company median returns against offer of minus 43.2% for the 2024 class and minus 23.4% for the 2025 class, both with 62% below offer, for the 2026 class at plus 2.3%, and for the July 2026 sponsor-backed consumer listings returning 0.6% and 7.5% against biotech listings returning roughly 29% to 66%; EY Global IPO Trends Q2 2026, published 7 July 2026, for the Americas first-half 2026 class at plus 14% one day after offer and plus 11% at thirty days against plus 33% and plus 20% for the 2025 class; SEC Release 34-104450 (SR-NASDAQ-2025-068) for the $15 million minimum market value of unrestricted publicly held shares operative from around 17 January 2026; SEC Release 34-104464 (SR-NASDAQ-2025-104), filed 12 December 2025 and immediately effective, for Nasdaq's discretion to deny an initial listing that meets every stated requirement; SEC Release 34-105971 (SR-NASDAQ-2026-004) approved 22 July 2026 and the SEC Deputy Secretary's letter of 29 July 2026 for the $5 million continued-listing requirement being approved and then stayed, still stayed as of 5 August 2026; Stock Analysis, private company valuations, as of 5 to 6 August 2026, for 325 tracked private companies at an aggregate valuation of $5.3 trillion. Different publishers count US listings differently depending on their treatment of blank-check vehicles, micro-caps and foreign issuers, so figures from two counting bases are never combined in a single sentence here. Companion articles on this site cover whether the listing window is open at all, and what a continuation vehicle or secondary produces instead.